an acute increase in intraluminal pressure, 9 and exogenous administration of the sphingolipid ceramide, 6 can induce a switch to mt H 2 O 2 -mediated dilation, but the endogenous regulator of this shear-sensitive switch is not known.
C ardiovascular disease remains a pressing global health issue. One unifying pathogenic factor in the development of cardiovascular disease is endothelial dysfunction, manifest as an impaired vasodilatory response to increased blood flow (ie, shear stress), or pharmacological agonists, an abnormality typically associated with endothelial inflammation and oxidative stress. 1, 2 Although most interventions are aimed at mitigating the influence of a single risk factor pathway associated with endothelial dysfunction, such as diabetes mellitus or hypercholesterolemia, targeting the participating mechanisms of endothelial dysfunction itself is an exciting approach to combat cardiovascular diseases, such as atherosclerosis. 3 Microvascular dysfunction is strongly prognostic for cardiovascular events, 4 suggesting that endothelial mechanisms in the microcirculation carry disease significance as either indicators of or underlying contributors to cardiovascular disease. However, microvascular dysfunction in humans has not been extensively examined. We have reported that the mediator of microcirculatory dilation to shear stress, the most physiologically important mechanism of endothelium-dependent dilation, is different between healthy and diseased vessels. NO elicits flow-mediated dilation (FMD) in vessels from subjects without cardiovascular disease. In contrast, in vessels from subjects with coronary artery disease (CAD), NO bioavailability is reduced as NO reacts with rising endothelial superoxide levels, and microvascular dilation is maintained by compensatory release of mitochondria-derived hydrogen peroxide ( mt H 2 O 2 ). [5] [6] [7] Excessive mt H 2 O 2 production can contribute to an inflammatory vascular milieu 8 and may be a key early pathogenic step in the progression of CAD. Pathological stimuli associated with CAD, including telomerase inhibition, In this study, we sought to elucidate a novel role for the transcriptional coactivator PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) in regulating the mechanism of dilation in the human microcirculation. Although largely studied in relation to obesity, skeletal muscle, and diabetes mellitus, interest in the vascular effects of PGC-1α and its protective role in atherogenesis has risen in the past several years. [10] [11] [12] [13] Given the shear-sensitive, 14 redox-modulating 15 vascular properties of PGC-1α, as well as its known interaction with NO in cultured endothelial cells and animal vessels, 16, 17 we considered whether PGC-1α could be an endogenous switch determining the mechanism of FMD between health and disease. We hypothesized that loss of PGC-1α in non-CAD arterioles produces a CAD phenotype, characterized by a switch from NO-mediated to mt H 2 O 2 -mediated dilation. We further hypothesized that PGC-1α upregulation in microvessels from subjects with CAD will restore a non-CAD vascular phenotype characterized by a return to NO-mediated dilation. We discovered that PGC-1α upregulation uniquely recruits both NO and H 2 O 2 during FMD, and protects against acute increases in intraluminal pressure, in vessels from subjects with CAD.
Methods

Materials
ZLN005 (Sigma), a known small-molecule activator of PGC-1α, 18, 19 was prepared in dimethyl sulfoxide. Bio-Enhanced Na-Rala (GeroNova Research) was dissolved in distilled water. Endothelin-1 (Sigma) was prepared in 1% bovine serum albumin. Lentiviral constructs (GFP [green fluorescent protein] and PGC-1α siRNA) were produced by the Blood Center of Wisconsin Hybridoma Core Laboratory and dissolved in distilled water. mitoPBA/mitoB (Cayman) was prepared in ethanol. Rotenone (Sigma) and MitoPY1 (Cayman) were prepared in DMSO.
Statistical Analysis
Data are expressed as mean±SEM. FMD is expressed as a percentage of maximal dilation to papaverine after endothelin-1 constriction. To compare flow-response relationships, a 2-way repeated-measures ANOVA was used with pressure gradient and intervention as parameters. When a significant difference was observed between control and inhibitor curves, responses at individual concentrations were compared using a Holm-Sidak multiple comparison test. An unpaired Students t test was used to compare baseline characteristics for patients with and without CAD. Differences in Western blot protein levels and H 2 O 2 production in human umbilical vein endothelial cells (HUVECs) were also assessed with an unpaired Student t test. Analyses were performed using SigmaPlot and GraphPad. Statistical significance was defined as P<0.05.
Results
Subject Demographics
Discarded adipose tissue was obtained from 49 patients. Twenty-eight of those patients had a clinical diagnosis of CAD. Detailed patient demographics are summarized in Table  I (online-only Data Supplement).
PGC-1α Protein Levels Are Decreased in Heart Tissue From Subjects With CAD
To determine whether a decline in PGC-1α levels occurs in the presence of CAD, we compared PGC-1α protein expression in non-CAD and CAD human left ventricular tissue. Western blotting revealed that PGC-1α protein content is lower in human CAD tissue ( Figure I in the online-only Data Supplement). In human microvessels, we performed immunohistochemistry, which, although not quantitative, also suggests a reduction in staining for PGC-1α in the microvasculature of subjects with CAD ( Figure IIA versus Figure IID in the online-only Data Supplement). Therefore, a diagnosis of CAD is associated with a relative decline of PGC-1α in both the human heart and microcirculation.
PGC-1α Levels in the Human Microcirculation
Forty-eight-hour incubation with lentiviral PGC-1α siRNA decreased PGC-1α levels in non-CAD vessels relative to untreated control ( Figure IIA 
Downregulation of PGC-1α in Non-CAD Vessels Produces a CAD Phenotype
Treatment of non-CAD vessels with lentiviral PGC-1α siRNA established a CAD phenotype characterized by normal magnitude H 2 O 2 -mediated dilation to shear (inhibited by PEG [polyethylene glycol]-catalase) (% max diameter at 100 cm H 2 O: vehicle 81.3±4.3, PEG-catalase 0.7±9.6). In contrast, L-NAME (N G -nitro-l-arginine methyl ester), which abolishes dilation in untreated non-CAD vessels, had no effect on FMD after PGC-1α downregulation ( Figure 1C ) (% max diameter at 100 cm H 2 O: vehicle 81.3±4.3, L-NAME 71.9±6.3). These data suggest that loss of PGC-1α in non-CAD vessels shifts away from NO-mediated dilation and exposes H 2 O 2 as the compensatory vasodilator.
Because a relative reduction in PGC-1α levels is observed in CAD vessels, and CAD vessels dilate to mt H 2 O 2 , we anticipated that a forced downregulation of PGC-1α in non-CAD arterioles using siRNA would also result in the unmasking of compensatory H 2 O 2 production from the mitochondria. Indeed, after PGC-1α knockdown, rotenone (inhibitor of electron transport chain complex 1) and mitoPBA (mitochondria-targeted H 2 O 2 scavenger) both inhibited FMD ( Figure 1D ) (% max diameter at 100 cm H 2 O: vehicle 81.3±4.3, rotenone −6.3±9.6, mitoPBA 4.8±12.5).
To control for possible off-target effects of the lentivirus, we also treated non-CAD vessels with a lentivirus harboring a GFP segment. The mechanism of dilation in these non-CAD vessels was unchanged (ie, FMD was still inhibited by L-NAME; Figure 1A ) (% max diameter at 100 cm H 2 O: vehicle 77.2±10.1, L-NAME −10.9±10.8), and successful transfection of GFP into arterioles was confirmed ( Figure 1B ). These findings indicate that non-CAD vessels dilate to NO, consistent with our previous reports. 6, 7 Moreover, the switch from NO-to H 2 O 2 -mediated dilation that we observed in non-CAD vessels after PGC-1α downregulation originates from mitochondrial sources and is attributable to changes in PGC-1α levels, not the lentivirus itself.
Overexpression of PGC-1α Confers Vasodilatory Plasticity in CAD Vessels
After observing that the loss of PGC-1α in non-CAD vessels produces a switch to mt H 2 O 2 -mediated dilation, we hypothesized and ZLN005, a novel small molecule transcriptional activator of PGC-1α. 18, 19 Before treatment, PEG-catalase blocked dilation in CAD vessels ( Figure 2A ) (% max diameter at 100 cm H 2 O: vehicle 75.3±11.1, PEG-catalase 24.2±5.6), as we have previously observed. 6 Unexpectedly, PGC-1α overexpression in CAD vessels exposed a novel phenotype characterized by contributions of both NO and H 2 O 2 to FMD. After treatment with either ALA or ZLN005, dilation was only partly inhibited by either L-NAME or PEG-catalase. Instead, dilation was abolished after combined coincubation with both L-NAME and PEG-catalase after PGC-1α upregulation with these 2 distinct compounds ( Figure . We also compared the responses between PGC-1α overexpressing and control CAD vessels ( Figure 2D ), which indicates that PGC-1α overexpression using ZLN005 or ALA renders dilation in CAD vessels less susceptible to inhibition by catalase (% maximal dilation at 100 cm H 2 O flow in vessels that are: untreated: 24.2+5.6; versus ALA-treated: 56.3+11.0, and ZLN-treated: 54.4+8.5). Thus, although a component of NO-mediated dilation was restored in CAD vessels, Figure 1 . Effect of PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) downregulation on flow-mediated dilation (FMD) in non-coronary artery disease (CAD) vessels. A, The magnitude of FMD is preserved in human arterioles after 48-hour treatment with lentiviral GFP (green fluorescent protein). L-NAME (N G -nitro-l-arginine methyl ester; endothelial nitric oxide synthase inhibitor) acts to inhibit FMD. B, Confirmation of lentiviral GFP uptake in non-CAD vessel via immunohistochemistry. C, The magnitude of FMD is preserved in human arterioles after 48-hour treatment with PGC-1α siRNA. PEG (polyethylene glycol)-catalase (H 2 O 2 scavenger) acts to inhibit FMD, whereas L-NAME has no effect. D, To determine the source of H 2 O 2 following PGC-1α knockdown, vessels were incubated with mitochondria-targeted inhibitors rotenone (1 µmol/L) and mitoPBA (5 µmol/L) for 30 minutes before initiation of flow. n=4 to 7 per treatment condition. *P<0.05 vs control curves at specific pressure gradients. we observed a maintained contribution of H 2 O 2 to dilation, highlighting that forced PGC-1α overexpression allows for more than one dilator mechanism to be present and that inhibition of dilation can only be achieved by simultaneously interfering with NO production and scavenging H 2 O 2 .
Source of H 2 O 2 After Overexpression of PGC-1α in CAD Vessels
We next examined whether the mitochondria remain the subcellular source of H 2 O 2 after PGC-1α upregulation in CAD vessels. FMD in CAD vessels is mediated entirely by mt H 2 O 2 and can be inhibited by either PEG-catalase or specific mitochondrial H 2 O 2 inhibitors or scavengers. 5 In contrast, after PGC-1α overexpression in CAD vessels, these mitochondrial inhibitors (in combination with L-NAME) no longer influenced FMD ( Figure 3B ). These findings suggest that, despite the continued presence of H 2 O 2 as a vasodilator, there is a transition away from the mt H 2 O 2 production observed in untreated CAD vessels.
To further investigate these findings using a complementary technique, we assessed mt H 2 O 2 production using a mitochondria-targeted H 2 O 2 probe (MitoPY1) in untreated and PGC-1α-overexpressing CAD vessels. Exposure of these vessels to shear stress revealed that PGC-1α overexpression suppresses mt H 2 O 2 production in ALA-treated vessels from subjects with CAD relative to untreated CAD vessels ( Figure 3A) .
Overexpression of PGC-1α Leads to Simultaneous Release of Both NO and H 2 O 2 in HUVECs in Response to Shear
To confirm the dual release of NO and H 2 O 2 , PGC-1α-overexpressing HUVECs were exposed to shear stress (15 dynes/cm 2 ) for 1 hour, and levels of NO and H 2 O 2 were determined relative to untreated, sheared HUVEC controls. DAF-2 (4,5-diaminofluorescein diacetate) fluorescence signal (NO) increased in ALA-treated versus untreated sheared cells ( Figure  4A ), illustrating the increase in NO production in response to shear stress as a result of increasing endothelial PGC-1α levels. Amplex Red fluorescence signal (H 2 O 2 ) also increased after shear in ALA-treated versus untreated cells, indicating that H 2 O 2 release is elevated in response to shear stress after PGC-1α overexpression ( Figure 4B ). To determine whether shearinduced H 2 O 2 release occurs tonically (basal release) or only after inhibition of NO production (compensatory release), we repeated the Amplex Red measurements after 30-minute incubation with L-NAME to block NO production. No change in the Amplex Red fluorescence signal was observed when NO was inhibited ( Figure 4B ), suggesting that H 2 O 2 coexists alongside NO during shear and is not acting as a compensatory vasodilator that only emerges when NO bioavailability is reduced.
Overexpression of PGC-1α Does Not Reduce Antioxidant Levels
Because endogenous antioxidants modulate H 2 O 2 levels in the vasculature, we evaluated whether the appearance of H 2 O 2 as a vasodilator was associated with a loss of antioxidant defense mechanisms in HUVECs. Interestingly, PGC-1α upregulation did not lead to a decrease in either catalase or MnSOD levels in ALA-treated HUVECs ( Figure 4C and 4D) , revealing maintained antioxidant defense mechanisms alongside the increase in H 2 O 2 production.
Overexpression of PGC-1α Protects Against Acute Increases in Intraluminal Pressure
After observing this novel phenotype wherein more than one vasodilator contributes to dilation in the presence of chronic disease (CAD), we sought to determine the functional relevance of this discovery. We questioned whether this additional vasodilatory plasticity confers a broader increased protection against acute vascular insults. Adipose microvessels from subjects with CAD experienced a severely impaired dilation to flow after 30-minute exposure to increased intraluminal pressure (IILP; 150 mm Hg) (% max diameter at 100 cm H 2 O: vehicle 75.3±4.3, IILP 22.7±10.7). In contrast, PGC-1α upregulation with ALA fully prevented IILP-induced vascular dysfunction, showing no reduction in maximal FMD after exposure to IILP ( Figure 5A ). Endothelium-independent dilation to papaverine was not different between the treatment groups ( Figure 5B ), highlighting that our results are related to endothelial-dependent mechanisms. 
Discussion
There are several major findings of this study. First, we have identified a functionally relevant effect of PGC-1α on FMD, adopting a reverse translational approach in human tissue to explore the reported link between the loss of PGC-1α and the development of CAD. As hypothesized, the loss of PGC-1α in non-CAD arterioles produced a diseased (CAD) phenotype characterized by a shift from NO-to mt H 2 O 2 -mediated dilation to flow, positioning PGC-1α as a key factor in microvascular atherosclerotic disease development. Second and unexpectedly, restoring PGC-1α in vessels from subjects with CAD produced a novel phenotype wherein both NO and H 2 O 2 contribute to dilation. Third, the source of H 2 O 2 was no longer mitochondrial in CAD vessels after PGC-1α upregulation. Fourth, the maintained, nonmitochondrial H 2 O 2 release was accompanied by conserved mitochondrial and cytosolic antioxidant expression. From a therapeutic perspective, we have identified 2 distinct compounds, ALA and ZLN005, that can produce upregulation of PGC-1α in the human microcirculation. We have uncovered a novel phenotype characterized by the simultaneous presence of NO and H 2 O 2 , lending plasticity to the mechanism of dilation to shear. We also report that microvascular FMD in CAD vessels is severely compromised after increased intraluminal pressure (IILP) (more so than non-CAD vessels 9 ) and that PGC-1α provides protection against this IILP-induced vascular dysfunction. These findings position PGC-1α as a promising therapeutic target for the microvascular complications of CAD via attenuation of mt H 2 O 2 release during shear, restoration of antiatherogenic NO as a vasodilator, and added resistance to acute barotrauma in CAD vessels.
That PGC-1α overexpression results in the coexistence of 2 vasodilators, NO and H 2 O 2 , which are canonically viewed as antagonistic, warrants additional discussion. H 2 O 2 is traditionally viewed as a prothrombotic and proinflammatory vasoactive substance that contributes to atherosclerotic disease burden. 8 However, recent evidence suggests that NO and H 2 O 2 may act in a synergistic fashion in certain circumstances, such as H 2 O 2 -induced activation of endothelial NOS, 20, 21 and that H 2 O 2 may even function as a primary mediator of dilation in healthy animal models. 20, [22] [23] [24] In addition, the detrimental effects of H 2 O 2 in relation to cardiovascular disease are mainly attributable to the source (mitochondria localized) and local concentrations of H 2 O 2 . [25] [26] [27] For example, recent evidence suggests that NOX4-derived H 2 O 2 is atheroprotective 28, 29 and can improve vasodilation without harmful oxidative effects on the vascular wall. 30 Data from other laboratories illustrate that excessive NO, and deficient H 2 O 2 , may increase, rather than decrease, endothelial dysfunction and that achieving moderate levels of these 2 vasodilators simultaneously is most cardioprotective. 31, 32 Although recent studies provide evidence to support this stance, few provide therapeutic strategies or molecular mechanisms to achieve this homeostatic balance between these 2 vasodilators. Given our results, PGC-1α may serve as a fundamental "molecular switch" that unlocks this compensatory pathway wherein NO and H 2 O 2 contribute to dilation, providing a window to advance our understanding surrounding this issue.
Our data support the protective role of H 2 O 2 by demonstrating that the presence of >1 vasodilator (NO and H 2 O 2 ) in CAD vessels fully preserves the overall magnitude of FMD after exposure to acute hypertension, a stimulus known to precipitate endothelial damage, 33 impair microvascular FMD, 9 and worsen development of CAD. 34, 35 This endothelial resilience after PGC-1α upregulation is not observed after acute hypertension in vessels relying on a single mediator, including both CAD vessels (H 2 O 2 ) and non-CAD vessels (NO). 9 This observation underscores that PGC-1α upregulation not only restores NO bioavailability and reduces mt H 2 O 2 (ie, reversal of the CAD phenotype) but also confers additional protection against barotrauma within the context of CAD. This finding corroborates the antihypertensive effects of PGC-1α described in a recent mouse model of angiotensin II infusion. 17 Given the known relationship between PGC-1α and mitochondrial dynamics, [36] [37] [38] [39] [40] and the results from previous studies in our laboratory indicating a central role for mt H 2 O 2 , we chose to examine the contribution of mt H 2 O 2 during FMD during PGC-1α knockdown in non-CAD vessels and PGC-1α upregulation in CAD vessels. We further demonstrate the continued presence of H 2 O 2 , but no longer of mitochondrial H 2 O 2 , in PGC-1α-overexpressing CAD vessels, emphasizing that one must look beyond the mere presence of H 2 O 2 and focus on its more specific subcellular source. It is also possible that there is a concentrationdependent effect of H 2 O 2 , with low levels serving a physiological role while high levels are detrimental. 41 Our data highlight that H 2 O 2 production may exist alongside conserved antioxidant defense mechanisms. This is a particularly intriguing finding, considering the high-profile failure of several global exogenous antioxidant trials in the past, 42, 43 believed to be the result of blocking pathological reactive oxygen species (ROS) in addition to the physiological ROS needed for proper cellular signaling. As a result, recent attempts to develop and clinically test more targeted antioxidants (MitoQ, Mito-VitE) that specifically limit mitochondrial-rather than total cellular-free radical production have been reported, 44, 45 with preliminary preclinical results describing the beneficial effects of these compounds within the context of cardiovascular disease. 27, 46 Our results suggest that PGC-1α upregulation may be an effective strategy to specifically dampen mt ROS production, in the same manner as MitoQ and MitoVitE, while also preserving endogenous antioxidant levels and promoting release of cellular, nonmitochondrial H 2 O 2 . The mechanism underlying this relationship between PGC-1α and mt ROS production warrants continued investigation.
We do not identify the molecular event caused by PGC-1α overexpression that results in dual contributions of NO and H 2 O 2 to FMD. We speculate that several possibilities exist based on past literature. Caveolin-1 may act as a the mechanosensor regulating this pathway, given previous reports from the Shimokawa laboratory indicating that caveolin-1 may be a key mechanism responsible for setting the balance between NO and H 2 O 2 in resistance vessels. 32 Concerning potential intracellular mediators of this pathway, PKG-1α is downstream of both NO and H 2 O 2 and establishes equilibrium between NO and H 2 O 2 during dilation. 24, 47, 48 One pathway responsible for the decreased mt ROS production after PGC-1α overexpression may relate to increases in NO bioavailability. Because NO inhibits mtROS in vessels, 49 restoring NO in CAD vessels may decrease mtROS during FMD without impairing ROS formation at other sites.
We offer both practical and mechanistic rationales for the use of ALA, a compound that can be administered orally, as an adjunct treatment in cardiovascular disease via upregulation of NO bioavailability and downregulation of mt ROS. Several studies have noted broad associations between ALA supplementation and an improvement in cardiovascular parameters, such as brachial artery FMD in patients with CAD, 50 and our data both support and extend these previous findings. Of note, the concentration of lipoic acid that we used for incubation studies (250 μmol/L) is consistent with therapeutically achievable plasma concentrations of ALA found in human studies.
51
Limitations
Please see online-only Data Supplement for a complete list of study limitations.
Perspectives
This study suggests that the loss of PGC-1α is sufficient to shift the mechanism of FMD from NO to H 2 O 2 , thus establishing a link between decreased PGC-1α and CAD pathogenesis in the microcirculation. Overexpression of PGC-1α has a beneficial effect in vessels from subjects with CAD by restoring a component of NO-mediated dilation and conferring protection against acute increases in intraluminal pressure. Lipoic acid supplementation has the potential to produce therapeutically advantageous effects in patients with CAD, but in-human clinical trials are needed to advance this concept.
